CO5190708A1 - Mezcla sinergica para el tratamiento del sindrome de piernas inquietas - Google Patents
Mezcla sinergica para el tratamiento del sindrome de piernas inquietasInfo
- Publication number
- CO5190708A1 CO5190708A1 CO00062316A CO00062316A CO5190708A1 CO 5190708 A1 CO5190708 A1 CO 5190708A1 CO 00062316 A CO00062316 A CO 00062316A CO 00062316 A CO00062316 A CO 00062316A CO 5190708 A1 CO5190708 A1 CO 5190708A1
- Authority
- CO
- Colombia
- Prior art keywords
- oral administration
- synergistic mixture
- mixture according
- dopa
- particularly preferably
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Mezcla sinérgica para el tratamiento del síndrome de piernas inquietas, que consta de un agonista a2 y otro neuro-psicofármaco que reduce los síntomas del RLS como una monoterapia.Mezcla sinérgica de acuerdo con la reivindicación 8, caracterizada porque el inhibidor de descarboxilasa es bencerazida o carbidopa o una de sus sales farmacológicamente compatibles.Mezcla sinérgica de acuerdo con la reivindicación 9, caracterizada porque la cantidad para L-DOPA en combinación con bencerazida corresponde a una administración por vía oral de 10 a 500 mg, preferiblemente de 10 a 200 mg y de modo particularmente preferido de 100 a 200 mg de L-DOPA y de 1 a 100 mg, preferiblemente de 10 a 50 mg y de modo particularmente preferido de 25 a 50 mg de bencerazida y para L-DOPA en combinación con carbidopa corresponde a una administración por vía oral de 10 a 500 mg, preferiblemente de 10 a 300 mg y de modo particularmente preferido de 50 a 200 mg de L-DOPA y de 1 a 100 mg, preferiblemente de 10 a 50 mg y de modo particularmente preferido de 12.5 a 50 mg de carbidopa.1Mezcla sinérgica de acuerdo con una de las reivindicaciones 1 a 7, caracterizada por el neuro- psicofármaco es un agente agonista de dopamina.1Mezcla sinérgica de acuerdo con la reivindicación 11, caracterizada porque el agente agonista de dopamina se selecciona entre el grupo formado por bromocriptina, cabergolina, a-dihidro-ergocriptina, lisurida, pergolida, piripedila, pramipexol (HCI) ropinirol, S( - )-2-(N-propil-N-2-tienil-etil-amino)-5-hidroxi-tetralina (p.ej. como N-O923) o (R)-5,6-dihidro-5-(metilamino)-4H-imidazo(4,5,1-il) quinolin-2-(1H)-ona R-6 (PNU 95666) o una de sus sales farmacológicamente compatibles.1Mezcla sinérgica de acuerdo con la reivindicación 12, caracterizada porque la cantidad correspondepara bromocriptina a una administración por vía oral de 1.25 a 20.0 mg, preferiblemente de 2.5 a 15.0 mg,para cabergolina a una administración por vía oral de 0.05 a 5.0 mg, preferiblemente de 0.5 a 3.0 mg,para a-dihidro-ergocriptina a una administración por vía oral de 5 a 60 mg, preferiblemente de 10 a 40 mg,para lisurida a una administración por vía oral de 0.1 a 5 mg, preferiblemente de 0.1 a 1.0 mg,para pergolida a una administración por vía oral de 0.05 a 1.0 mg preferiblemente de 0.1 a 1.0 mg,para pramipexol (HCI) a una administración por vía oral de 0.01 a 5.0 mg preferiblemente de 0.1 a 1.5 mg, de modo particularmente preferido de 0.125 a 1.0 mg ypara ropinirol a una administración por vía oral de 0.2 a 10.0 mg, preferiblemente de 0.25 a 6.0 mg.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19938823A DE19938823A1 (de) | 1999-08-19 | 1999-08-19 | Medikamentöse Behandlung des Restless Leg Syndroms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5190708A1 true CO5190708A1 (es) | 2002-08-29 |
Family
ID=7918572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00062316A CO5190708A1 (es) | 1999-08-19 | 2000-08-18 | Mezcla sinergica para el tratamiento del sindrome de piernas inquietas |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20010053777A1 (es) |
| EP (1) | EP1210076A2 (es) |
| JP (1) | JP2003513014A (es) |
| KR (1) | KR20020020273A (es) |
| CN (1) | CN1368878A (es) |
| AR (1) | AR025329A1 (es) |
| AU (1) | AU6836500A (es) |
| BR (1) | BR0013355A (es) |
| CA (1) | CA2382648A1 (es) |
| CO (1) | CO5190708A1 (es) |
| CZ (1) | CZ2002516A3 (es) |
| DE (1) | DE19938823A1 (es) |
| IL (1) | IL147643A0 (es) |
| MX (1) | MXPA02001295A (es) |
| NO (1) | NO20020792L (es) |
| PE (1) | PE20010738A1 (es) |
| PL (1) | PL364871A1 (es) |
| SK (1) | SK2452002A3 (es) |
| TR (1) | TR200200450T2 (es) |
| UY (1) | UY26296A1 (es) |
| WO (1) | WO2001013903A2 (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1685839T1 (sl) | 1997-12-22 | 2013-08-30 | Euro-Celtique S.A. | Farmacevtska oralna dozirna oblika, ki vsebuje kombinacijo opioidnega agonista in opioidnega antagonista |
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| CN1554341A (zh) * | 2000-04-21 | 2004-12-15 | �������Ŷ���Լ��������˾ | 用于治疗纤维肌痛和慢性疲劳综合症的化合物 |
| EP1280530A1 (en) * | 2000-04-21 | 2003-02-05 | PHARMACIA & UPJOHN COMPANY | Treatment of fibromyalgia and chronic fatigue syndrome |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| US20070243240A9 (en) * | 2000-08-24 | 2007-10-18 | Fred Windt-Hanke | Transdermal therapeutic system |
| DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| AR031152A1 (es) * | 2000-10-31 | 2003-09-10 | Upjohn Co | Tratamientos nuevos para el sindrome de piernas inquietas |
| US8338442B2 (en) | 2001-03-30 | 2012-12-25 | Toray Industries, Inc. | Remedies for psychoneurosis |
| WO2002083141A1 (en) * | 2001-04-17 | 2002-10-24 | Pharmacia & Upjohn Company | Treatment of fibromyalgia and chronic fatigue syndrome |
| CN1525851A (zh) | 2001-05-11 | 2004-09-01 | ������ҩ������˾ | 抗滥用阿片样物质控释剂型 |
| US20030073609A1 (en) * | 2001-06-29 | 2003-04-17 | Pinkerton Thomas C. | Enhanced pharmacokinetic profile of intradermally delivered substances |
| DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| US20060263419A1 (en) * | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
| KR20040098050A (ko) | 2002-04-05 | 2004-11-18 | 유로-셀띠끄 소시에떼 아노님 | 옥시코돈 및 날록손을 포함하는 약제학적 제제 |
| DE10220230A1 (de) * | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
| PL372695A1 (en) * | 2002-06-19 | 2005-07-25 | Solvay Pharmaceuticals Gmbh | Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins |
| US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
| US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
| ES2239196T3 (es) | 2002-12-02 | 2005-09-16 | Schwarz Pharma Ag | Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson. |
| DE10338174A1 (de) * | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| EP1604667A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
| EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
| JP5704789B2 (ja) * | 2005-01-28 | 2015-04-22 | ユーロ−セルティーク エス．エイ． | 耐アルコール性剤形 |
| EP1695700A1 (en) * | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
| EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
| EP1813276A1 (en) * | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
| JP5769923B2 (ja) | 2006-04-03 | 2015-08-26 | テバ ファーマシューティカル インダストリーズ リミティド | レストレスレッグス症候群の治療のためのラサギリンの使用 |
| US20100029618A1 (en) * | 2006-12-22 | 2010-02-04 | Gil Daniel W | Alpha-2 receptor pan agonist and anticonvulsant compositions for treating chronic pain |
| US20110097393A1 (en) * | 2008-06-25 | 2011-04-28 | US WorldMeade, LLC | Skin Patches and Sustained-Release Formulations Comprising Lofexidine for Transdermal and Oral Delivery |
| EP2405915B1 (en) | 2009-03-10 | 2018-10-24 | Euro-Celtique S.A. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
| US20180264013A1 (en) * | 2010-07-08 | 2018-09-20 | Wellesley Pharmaceuticals, Llc | Composition and methods for treating sleep disorders |
| MX2014015266A (es) * | 2012-06-11 | 2015-06-23 | Psychogenics Inc | Tratamiento de efectos secundarios de trastorno motriz y del movimiento asociados con tratamientos de enfermedad de parkinson. |
| NZ716267A (en) | 2013-07-23 | 2017-05-26 | Euro Celtique Sa | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
| TWI629066B (zh) | 2013-10-07 | 2018-07-11 | 帝國製藥美國股份有限公司 | 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物 |
| RU2018105761A (ru) | 2013-10-07 | 2019-02-26 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Устройства для трансдермальной доставки дексмедетомидина и способы их применения |
| RU2648449C2 (ru) | 2013-10-07 | 2018-03-26 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина |
| CN110446533A (zh) * | 2016-09-13 | 2019-11-12 | 思想实验室有限责任公司 | 不宁腿综合征的药品组合与治疗 |
| SI3906927T1 (sl) * | 2020-05-04 | 2022-08-31 | Bioprojet Pharma | Uporaba delnih agonistov dopamina D3 za zdravljenje motenj centralnega živčnega sistema |
| CN115154448B (zh) * | 2022-08-04 | 2024-01-30 | 谭竞 | 一种治疗不宁腿综合征的药物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4859685A (en) * | 1986-08-13 | 1989-08-22 | Boc, Inc. | Anesthetic composition and method of using the same |
| DE19758564A1 (de) * | 1997-11-11 | 1999-08-26 | Gruenenthal Gmbh | Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung |
| SE9803760D0 (sv) * | 1998-11-04 | 1998-11-04 | Jan Hedner | Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel |
| AU3490300A (en) * | 1999-03-12 | 2000-10-04 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
-
1999
- 1999-08-19 DE DE19938823A patent/DE19938823A1/de not_active Withdrawn
-
2000
- 2000-08-09 TR TR2002/00450T patent/TR200200450T2/xx unknown
- 2000-08-09 EP EP00956413A patent/EP1210076A2/de not_active Withdrawn
- 2000-08-09 SK SK245-2002A patent/SK2452002A3/sk unknown
- 2000-08-09 AU AU68365/00A patent/AU6836500A/en not_active Abandoned
- 2000-08-09 WO PCT/EP2000/007719 patent/WO2001013903A2/de not_active Application Discontinuation
- 2000-08-09 KR KR1020027002101A patent/KR20020020273A/ko not_active Application Discontinuation
- 2000-08-09 MX MXPA02001295A patent/MXPA02001295A/es unknown
- 2000-08-09 IL IL14764300A patent/IL147643A0/xx unknown
- 2000-08-09 CA CA002382648A patent/CA2382648A1/en not_active Abandoned
- 2000-08-09 BR BR0013355-8A patent/BR0013355A/pt active Pending
- 2000-08-09 CN CN00811555A patent/CN1368878A/zh active Pending
- 2000-08-09 CZ CZ2002516A patent/CZ2002516A3/cs unknown
- 2000-08-09 PL PL00364871A patent/PL364871A1/xx not_active Application Discontinuation
- 2000-08-09 JP JP2001518041A patent/JP2003513014A/ja active Pending
- 2000-08-16 UY UY26296A patent/UY26296A1/es not_active Application Discontinuation
- 2000-08-17 PE PE2000000835A patent/PE20010738A1/es not_active Application Discontinuation
- 2000-08-18 CO CO00062316A patent/CO5190708A1/es not_active Application Discontinuation
- 2000-08-18 AR ARP000104291A patent/AR025329A1/es active Pending
-
2001
- 2001-08-01 US US09/919,731 patent/US20010053777A1/en not_active Abandoned
-
2002
- 2002-02-18 NO NO20020792A patent/NO20020792L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL364871A1 (en) | 2004-12-27 |
| WO2001013903A3 (de) | 2001-08-23 |
| JP2003513014A (ja) | 2003-04-08 |
| WO2001013903A2 (de) | 2001-03-01 |
| CA2382648A1 (en) | 2001-03-01 |
| AR025329A1 (es) | 2002-11-20 |
| PE20010738A1 (es) | 2001-07-16 |
| UY26296A1 (es) | 2001-04-30 |
| SK2452002A3 (en) | 2002-06-04 |
| KR20020020273A (ko) | 2002-03-14 |
| BR0013355A (pt) | 2002-04-30 |
| DE19938823A1 (de) | 2001-02-22 |
| TR200200450T2 (tr) | 2002-08-21 |
| NO20020792D0 (no) | 2002-02-18 |
| NO20020792L (no) | 2002-02-18 |
| EP1210076A2 (de) | 2002-06-05 |
| AU6836500A (en) | 2001-03-19 |
| CN1368878A (zh) | 2002-09-11 |
| CZ2002516A3 (cs) | 2002-05-15 |
| MXPA02001295A (es) | 2002-08-12 |
| US20010053777A1 (en) | 2001-12-20 |
| IL147643A0 (en) | 2002-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5190708A1 (es) | Mezcla sinergica para el tratamiento del sindrome de piernas inquietas | |
| TW200505423A (en) | Combination, kit and pharmaceutical composition for treatment of parkinson's disease | |
| UY28135A1 (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal | |
| BRPI0506977A (pt) | composto de tetrahidrocarbolina como agentes anticáncer | |
| DK1689724T3 (da) | Quinazolinonforbindelser som anticancermidler | |
| AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
| TW200718689A (en) | 2-Amino-quinazolin-5-ones | |
| AR062860A1 (es) | Combinaciones terapeuticas 482 | |
| PA8507601A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
| HUP0303271A2 (hu) | Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására | |
| ECSP045379A (es) | Derivados de [1,4]diazepino[6,7,1-ij]quinolina como agentes antipsicóticos y contra la obesidad | |
| AR058163A1 (es) | Medicamentos exhaltadores del deseo sexual que comprenden derivados de benzimidazolona | |
| PA8502901A1 (es) | Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1 | |
| RU2011137131A (ru) | Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха | |
| DOP2001000289A (es) | Combinación de agonistas de gaba e inhibidores de sorbitol- deshidrogenasa | |
| CR6962A (es) | Combinacion de agonistas de gaba e inhibidores de aldosa-reductasa | |
| CO5200840A1 (es) | Combinacion de sustancias activas con clonidina | |
| BR0113291A (pt) | steres de aporfina e seu uso em terapia | |
| PE20010577A1 (es) | Composicion farmaceutica para la prevencion y tratamiento de la adiccion a la nicotina que comprende un agonista del receptor nicotinico, un agente antidepresivo o ansiolitico | |
| AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
| CO5540294A2 (es) | Una combinacion de un derivado de rapamicina y un agente alquilante seleccionado de ciclofosfamida y carmustina y composiciones que las contienen | |
| GT200000159A (es) | Sal polimorfica. | |
| AR062784A1 (es) | Tratmiento de los vertigos con acetil -l- leucina | |
| UY27401A1 (es) | Método para el tratamiento del insomnio primario |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |